Market revenue in 2024 | USD 15,924.8 million |
Market revenue in 2030 | USD 60,537.1 million |
Growth rate | 22.3% (CAGR from 2025 to 2030) |
Largest segment | Glp-1 receptor agonists |
Fastest growing segment | Other Drug Class |
Historical data covered | 2018 - 2023 |
Base year for estimation | 2024 |
Forecast period covered | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | GLP-1 Receptor Agonists, Lipase Inhibitors (Orlistat), Appetite Suppressants (Phentermine, Lorcaserin), Other Drug Class |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to obesity treatment market will help companies and investors design strategic landscapes.
Glp-1 receptor agonists was the largest segment with a revenue share of 115.67% in 2024. Horizon Databook has segmented the Global obesity treatment market based on glp-1 receptor agonists, lipase inhibitors (orlistat), appetite suppressants (phentermine, lorcaserin), other drug class covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of global-level data and insights on the Global obesity treatment market , including forecasts for subscribers. This global databook contains high-level insights into Global obesity treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account